Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Docetaxel and Cetuximab in Patients With Docetaxel-resistant Hormone-refractory Prostate Cancer (HRPC). A Multicenter Phase II Trial

NCT00728663 is registered in ClinicalTrials.gov with Swiss Cancer Institute as lead sponsor.

NCT NCT00728663
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00728663 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Docetaxel and Cetuximab in Patients With Docetaxel-resistant Hormone-refractory Prostate Cancer (HRPC). A Multicenter Phase II Trial
Lead sponsor
Swiss Cancer Institute
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2008
Completion date
April 30, 2010
Enrollment
35 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer